Presentations AHA 2022 presentation on VERVE-101 ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference Pagination Current page 1 Page 2 Next page next › Last page last »
AHA 2022 presentation on VERVE-101 ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference Pagination Current page 1 Page 2 Next page next › Last page last »
ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene